204 related articles for article (PubMed ID: 26261232)
21. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
22. ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD).
Liakopoulos S; Spital G; Brinkmann CK; Schick T; Ziemssen F; Voegeler J; Koch M; Kirchhof B; Holz FG; Pauleikhoff D; Schmitz-Valckenberg S
Br J Ophthalmol; 2020 Nov; 104(11):1573-1578. PubMed ID: 32066561
[TBL] [Abstract][Full Text] [Related]
23. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
24. IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL.
Wickremasinghe SS; Janakan V; Sandhu SS; Amirul-Islam FM; Abedi F; Guymer RH
Retina; 2016 Jul; 36(7):1331-9. PubMed ID: 26655608
[TBL] [Abstract][Full Text] [Related]
25. The Presence of Intra- or Subretinal Fluid during the Loading Phase in the Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab Assessed by Optical Coherence Tomography.
Ebneter A; Gekkiev B; Chanana B; Wolf S; Zinkernagel MS
Ophthalmologica; 2015; 234(2):61-6. PubMed ID: 25998752
[TBL] [Abstract][Full Text] [Related]
26. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
27. MINIMAL OPTICAL COHERENCE TOMOGRAPHY B-SCAN DENSITY FOR RELIABLE DETECTION OF INTRARETINAL AND SUBRETINAL FLUID IN MACULAR DISEASES.
Fang PP; Domdei N; Herrmann P; Schmitz-Valckenberg S; Holz FG; Harmening WM; Krohne TU
Retina; 2019 Jan; 39(1):150-156. PubMed ID: 29095359
[TBL] [Abstract][Full Text] [Related]
28. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration.
Shah VP; Shah SA; Mrejen S; Freund KB
Retina; 2014 Jul; 34(7):1281-8. PubMed ID: 24695062
[TBL] [Abstract][Full Text] [Related]
29. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
30. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.
Kumar N; Marsiglia M; Mrejen S; Fung AT; Slakter J; Sorenson J; Freund KB
Retina; 2013 Sep; 33(8):1605-12. PubMed ID: 23549101
[TBL] [Abstract][Full Text] [Related]
31. Relationship Between Subretinal Hyperreflective Material Reflectivity and Volume in Patients With Neovascular Age-Related Macular Degeneration Following Anti-Vascular Endothelial Growth Factor Treatment.
Charafeddin W; Nittala MG; Oregon A; Sadda SR
Ophthalmic Surg Lasers Imaging Retina; 2015 May; 46(5):523-30. PubMed ID: 26057755
[TBL] [Abstract][Full Text] [Related]
32. Significance of the hyperautofluorescent ring associated with choroidal neovascularisation in eyes undergoing anti-VEGF therapy for wet age-related macular degeneration.
Camacho N; Barteselli G; Nezgoda JT; El-Emam S; Cheng L; Bartsch DU; Freeman WR
Br J Ophthalmol; 2015 Sep; 99(9):1277-83. PubMed ID: 25777818
[TBL] [Abstract][Full Text] [Related]
33. Gray hyper-reflective subretinal exudative lesions in exudative age-related macular degeneration.
Ores R; Puche N; Querques G; Blanco-Garavito R; Merle B; Coscas G; Oubraham H; Semoun O; Souied EH
Am J Ophthalmol; 2014 Aug; 158(2):354-61. PubMed ID: 24794284
[TBL] [Abstract][Full Text] [Related]
34. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
[TBL] [Abstract][Full Text] [Related]
35. OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy.
Kuehlewein L; Sadda SR; Sarraf D
Eye (Lond); 2015 Jul; 29(7):932-5. PubMed ID: 25976641
[TBL] [Abstract][Full Text] [Related]
36. VALIDATION OF AN AUTOMATED FLUID ALGORITHM ON REAL-WORLD DATA OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OVER FIVE YEARS.
Gerendas BS; Sadeghipour A; Michl M; Goldbach F; Mylonas G; Gruber A; Alten T; Leingang O; Sacu S; Bogunovic H; Schmidt-Erfurth U
Retina; 2022 Sep; 42(9):1673-1682. PubMed ID: 35994584
[TBL] [Abstract][Full Text] [Related]
37. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion.
Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S
Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942
[TBL] [Abstract][Full Text] [Related]
38. Geographic atrophy in patients receiving anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Xu L; Mrejen S; Jung JJ; Gallego-Pinazo R; Thompson D; Marsiglia M; Freund KB
Retina; 2015 Feb; 35(2):176-86. PubMed ID: 25387047
[TBL] [Abstract][Full Text] [Related]
39. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
[TBL] [Abstract][Full Text] [Related]
40. [Effectiveness of anti-VEGF therapy for neovascular age-related macular degeneration in different types of exudative fluid localization].
Budzinskaya MV; Afanasyeva MA; Plyukhova AA; Novikov IA; Shelankova AV; Andreeva IV
Vestn Oftalmol; 2021; 137(6):12-17. PubMed ID: 34965062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
